Sotera Health (NASDAQ:SHC) Updates FY 2025 Earnings Guidance

Sotera Health (NASDAQ:SHC) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 0.700-0.760 for the period, compared to the consensus EPS estimate of 0.780. The company issued revenue guidance of $1.1 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on SHC shares. Citigroup raised their target price on shares of Sotera Health from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. Royal Bank of Canada restated an “outperform” rating and set a $17.00 price objective on shares of Sotera Health in a report on Thursday, November 21st. Barclays lowered their price objective on Sotera Health from $17.00 to $16.00 and set an “overweight” rating for the company in a research report on Friday. Finally, The Goldman Sachs Group started coverage on Sotera Health in a research note on Friday, December 6th. They issued a “neutral” rating and a $14.00 price target on the stock. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.92.

Sotera Health Price Performance

Shares of Sotera Health stock opened at $12.47 on Friday. The business’s fifty day moving average price is $13.45 and its 200 day moving average price is $14.51. Sotera Health has a twelve month low of $10.71 and a twelve month high of $17.08. The company has a current ratio of 2.88, a quick ratio of 2.61 and a debt-to-equity ratio of 4.91. The stock has a market capitalization of $3.53 billion, a P/E ratio of 49.88 and a beta of 1.91.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.